{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:41:05Z","timestamp":1790250065034,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kidney transplant recipients (KTRs) face an increased risk of renal cell carcinoma (RCC), in which the immunosuppressive regimen plays an important role. This study aimed to identify intracellular signalling alterations associated with post-transplant (post-tx) tumour formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Expression of mTOR-related proteins were analysed in kidneys obtained from end-stage renal disease (ESRD) patients and RCCs developed in KTRs or non-transplant patients. The effects of tacrolimus (TAC) and rapamycin (RAPA) on mTOR activity, proliferation, and tumour growth were investigated through different in vitro and in vivo experiments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated mTORC1\/C2 activity was observed in post-tx RCCs and in kidneys of TAC-treated ESRD patients. In vitro experiments demonstrated that TAC increases mTOR activity in a normal tubular epithelial cell line and in the investigated RCC cell lines, moreover, promotes the proliferation of some RCC cell line. In vivo, TAC elevated mTORC1\/C2 activity in ischaemic kidneys of mice and enhanced tumour growth in xenograft model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We observed significantly increased mTOR activity in ischaemic kidneys and post-tx RCCs, which highlights involvement of mTOR pathway both in the healing or fibrotic processes of kidney and in tumorigenesis. TAC-treatment further augmented the already elevated mTOR activity of injured kidney, potentially contributing to tumorigenesis during immunosuppression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-024-02597-8","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T07:02:20Z","timestamp":1707548540000},"page":"1119-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tumorigenic role of tacrolimus through mTORC1\/C2 activation in post-transplant renal cell carcinomas"],"prefix":"10.1038","volume":"130","author":[{"given":"Dorottya","family":"Moldvai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Sztankovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titanilla","family":"Dank\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enik\u0151","family":"Vetl\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Pet\u0151v\u00e1ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"M\u00e1rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Patonai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"V\u00e9gs\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Piros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1d\u00e1m","family":"Hossz\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"P\u00e1pay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Krencz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-4794","authenticated-orcid":false,"given":"Anna","family":"Sebesty\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"2597_CR1","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1111\/ajt.13862","volume":"16","author":"S Karami","year":"2016","unstructured":"Karami S, Yanik EL, Moore LE, Pfeiffer RM, Copeland G, Gonsalves L, et al. Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States. Am J Transpl. 2016;16:3479\u201389.","journal-title":"Am J Transpl"},{"key":"2597_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/ijc.33934","volume":"150","author":"TK Friman","year":"2022","unstructured":"Friman TK, J\u00e4\u00e4maa-Holmberg S, \u00c5berg F, Helanter\u00e4 I, Halme M, Pentik\u00e4inen MO, et al. Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland. Int J Cancer. 2022;150:1779\u201391.","journal-title":"Int J Cancer"},{"key":"2597_CR3","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.transproceed.2015.07.021","volume":"47","author":"G V\u00e9gs\u0151","year":"2015","unstructured":"V\u00e9gs\u0151 G, T\u00f3th A, Toronyi \u00c9, Perner F, M\u00e1th\u00e9 Z. Changes in Tumor Characteristics in Kidney Transplanted Patients Over the Last 40 Years. Transpl Proc. 2015;47:2198\u2013200.","journal-title":"Transpl Proc"},{"key":"2597_CR4","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.kint.2020.10.018","volume":"99","author":"CD Blosser","year":"2021","unstructured":"Blosser CD, Haber G, Engels EA. Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. Kidney Int. 2021;99:1430\u20138.","journal-title":"Kidney Int"},{"key":"2597_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0896-8411(89)80010-1","volume":"2","author":"IT Cockburn","year":"1989","unstructured":"Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 1989;2:723\u201331.","journal-title":"J Autoimmun"},{"key":"2597_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","volume":"351","author":"J Dantal","year":"1998","unstructured":"Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351:623\u20138.","journal-title":"Lancet"},{"key":"2597_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2133.2004.06315.x","volume":"152","author":"T Langeland","year":"2005","unstructured":"Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol. 2005;152:183\u20135.","journal-title":"Br J Dermatol"},{"key":"2597_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/CLEP.S146442","volume":"10","author":"J Castellsague","year":"2018","unstructured":"Castellsague J, Kuiper JG, Potteg\u00e5rd A, Anveden Berglind I, Dedman D, Gutierrez L, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018;10:299\u2013310.","journal-title":"Clin Epidemiol"},{"key":"2597_CR9","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2020.2240","volume":"156","author":"MM Asgari","year":"2020","unstructured":"Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis. JAMA Dermatol. 2020;156:1066\u201373.","journal-title":"JAMA Dermatol"},{"key":"2597_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2147\/CLEP.S331287","volume":"13","author":"A Arana","year":"2021","unstructured":"Arana A, Potteg\u00e5rd A, Kuiper JG, Booth H, Reutfors J, Calingaert B, et al. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clin Epidemiol. 2021;13:1141\u201353.","journal-title":"Clin Epidemiol"},{"key":"2597_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","volume":"7","author":"N Devasenapathy","year":"2023","unstructured":"Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7:13\u201325.","journal-title":"Lancet Child Adolesc Health"},{"key":"2597_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2133.2008.08974.x","volume":"160","author":"NA Undre","year":"2009","unstructured":"Undre NA, Moloney FJ, Ahmadi S, Stevenson P, Murphy GM. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2009;160:665\u20139.","journal-title":"Br J Dermatol"},{"key":"2597_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1139\/y77-007","volume":"55","author":"RR Martel","year":"1977","unstructured":"Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharm. 1977;55:48\u201351.","journal-title":"Can J Physiol Pharm"},{"key":"2597_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.7164\/antibiotics.37.1231","volume":"37","author":"CP Eng","year":"1984","unstructured":"Eng CP, Sehgal SN, V\u00e9zina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot. 1984;37:1231\u20137.","journal-title":"J Antibiot"},{"key":"2597_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:706\u201320.","journal-title":"Ann Oncol"},{"key":"2597_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","volume":"31","author":"SN Sehgal","year":"1998","unstructured":"Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335\u201340.","journal-title":"Clin Biochem"},{"key":"2597_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ajt.12969","volume":"15","author":"EL Yanik","year":"2015","unstructured":"Yanik EL, Gustafson SK, Kasiske BL, Israni AK, Snyder JJ, Hess GP, et al. Sirolimus use and cancer incidence among US kidney transplant recipients. Am J Transpl. 2015;15:129\u201336.","journal-title":"Am J Transpl"},{"key":"2597_CR18","doi-asserted-by":"publisher","first-page":"g6679","DOI":"10.1136\/bmj.g6679","volume":"349","author":"GA Knoll","year":"2014","unstructured":"Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679.","journal-title":"BMJ"},{"key":"2597_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/TP.0000000000004336","volume":"107","author":"K Schmucki","year":"2023","unstructured":"Schmucki K, Hofmann P, Fehr T, Inci I, Kohler M, Schuurmans MM. Mammalian Target of Rapamycin Inhibitors and Kidney Function After Thoracic Transplantation: A Systematic Review and Recommendations for Management of Lung Transplant Recipients. Transplantation. 2023;107:53\u201373.","journal-title":"Transplantation"},{"key":"2597_CR20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/ckj\/sfaa262","volume":"14","author":"MG Naik","year":"2021","unstructured":"Naik MG, Arns W, Budde K, Diekmann F, Eitner F, Gwinner W, et al. Sirolimus in renal transplant recipients with malignancies in Germany. Clin Kidney J. 2021;14:2047\u201358.","journal-title":"Clin Kidney J"},{"key":"2597_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","volume":"87","author":"FP Schena","year":"2009","unstructured":"Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233\u201342.","journal-title":"Transplantation"},{"key":"2597_CR22","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/1097-0142(19930901)72:5<1779::AID-CNCR2820720543>3.0.CO;2-M","volume":"72","author":"A Trattner","year":"1993","unstructured":"Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer. 1993;72:1779\u201383.","journal-title":"Cancer"},{"key":"2597_CR23","doi-asserted-by":"crossref","unstructured":"Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis. Am J Transplant. 2016;16:3490\u2013503.","DOI":"10.1111\/ajt.13863"},{"key":"2597_CR24","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","volume":"296","author":"CM Vajdic","year":"2006","unstructured":"Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. Jama. 2006;296:2823\u201331.","journal-title":"Jama"},{"key":"2597_CR25","doi-asserted-by":"publisher","first-page":"e0122442","DOI":"10.1371\/journal.pone.0122442","volume":"10","author":"TP Huynh","year":"2015","unstructured":"Huynh TP, Barwe SP, Lee SJ, McSpadden R, Franco OE, Hayward SW, et al. Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,K-ATPase beta-1 subunit expression. PLoS One. 2015;10:e0122442.","journal-title":"PLoS One"},{"key":"2597_CR26","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/ndt\/gfw304","volume":"31","author":"H Engberg","year":"2016","unstructured":"Engberg H, Wehberg S, Bistrup C, Heaf J, S\u00f8rensen SS, Thiesson HC, et al. Cancer risk and mortality after kidney transplantation: a population-based study on differences between Danish centres using standard immunosuppression with and without glucocorticoids. Nephrol Dial Transpl. 2016;31:2149\u201356.","journal-title":"Nephrol Dial Transpl"},{"key":"2597_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bcp.14979","volume":"88","author":"P Hirunsatitpron","year":"2022","unstructured":"Hirunsatitpron P, Hanprasertpong N, Noppakun K, Pruksakorn D, Teekachunhatean S, Koonrungsesomboon N. Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis. Br J Clin Pharm. 2022;88:476\u201389.","journal-title":"Br J Clin Pharm"},{"key":"2597_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/00007890-199901150-00030","volume":"67","author":"OK Eberhard","year":"1999","unstructured":"Eberhard OK, Kliem V, Brunkhorst R. Five cases of Kaposi\u2019s sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Transplantation. 1999;67:180\u20134.","journal-title":"Transplantation"},{"key":"2597_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/00007890-199559040-00006","volume":"59","author":"I Penn","year":"1995","unstructured":"Penn I. Primary kidney tumors before and after renal transplantation. Transplantation. 1995;59:480\u20135.","journal-title":"Transplantation"},{"key":"2597_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.juro.2011.03.032","volume":"186","author":"M Leveridge","year":"2011","unstructured":"Leveridge M, Musquera M, Evans A, Cardella C, Pei Y, Jewett M, et al. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J Urol. 2011;186:219\u201323.","journal-title":"J Urol"},{"key":"2597_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.trre.2015.07.001","volume":"30","author":"X Tillou","year":"2016","unstructured":"Tillou X, Guleryuz K, Collon S, Doerfler A. Renal cell carcinoma in functional renal graft: Toward ablative treatments. Transpl Rev. 2016;30:20\u20136.","journal-title":"Transpl Rev"},{"key":"2597_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.humpath.2016.12.012","volume":"62","author":"I Krencz","year":"2017","unstructured":"Krencz I, Sebesty\u00e9n A, F\u00e1bi\u00e1n K, M\u00e1rk \u00c1, Moldvay J, Khoor A, et al. Expression of mTORC1\/2-related proteins in primary and brain metastatic lung adenocarcinoma. Hum Pathol. 2017;62:66\u201373.","journal-title":"Hum Pathol"},{"key":"2597_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/CBM-2011-0176","volume":"9","author":"P Cairns","year":"2010","unstructured":"Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9:461\u201373.","journal-title":"Cancer Biomark"},{"key":"2597_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","volume":"59","author":"RN Saunders","year":"2001","unstructured":"Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59:3\u201316.","journal-title":"Kidney Int"},{"key":"2597_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.krcp.2012.06.007","volume":"31","author":"SS Han","year":"2012","unstructured":"Han SS, Kim DH, Lee SM, Han NY, Oh JM, Ha J, et al. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Res Clin Pr. 2012;31:157\u201362.","journal-title":"Kidney Res Clin Pr"},{"key":"2597_CR36","doi-asserted-by":"crossref","unstructured":"Dank\u00f3 T, Pet\u0151v\u00e1ri G, Sztankovics D, Moldvai D, Raffay R, L\u0151rincz P, et al. Rapamycin Plus Doxycycline Combination Affects Growth Arrest and Selective Autophagy-Dependent Cell Death in Breast Cancer Cells. Int J Mol Sci. 2021;22:8019.","DOI":"10.3390\/ijms22158019"},{"key":"2597_CR37","doi-asserted-by":"crossref","unstructured":"Krencz I, Vetl\u00e9nyi E, Dank\u00f3 T, Pet\u0151v\u00e1ri G, Moldvai D, Sztankovics D, et al. Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics. Int J Mol Sci. 2022;23:10587.","DOI":"10.3390\/ijms231810587"},{"key":"2597_CR38","doi-asserted-by":"publisher","first-page":"1610996","DOI":"10.3389\/pore.2023.1610996","volume":"29","author":"D Sztankovics","year":"2023","unstructured":"Sztankovics D, Moldvai D, Pet\u0151v\u00e1ri G, Gelencs\u00e9r R, Krencz I, Raffay R, et al. 3D bioprinting and the revolution in experimental cancer model systems-A review of developing new models and experiences with in vitro 3D bioprinted breast cancer tissue-mimetic structures. Pathol Oncol Res. 2023;29:1610996.","journal-title":"Pathol Oncol Res"},{"key":"2597_CR39","doi-asserted-by":"crossref","unstructured":"Panizo S, Mart\u00ednez-Arias L, Alonso-Montes C, Cannata P, Mart\u00edn-Carro B, Fern\u00e1ndez-Mart\u00edn JL, et al. Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. Int J Mol Sci. 2021;22:408.","DOI":"10.3390\/ijms22010408"},{"key":"2597_CR40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1046\/j.1523-1755.2003.00750.x","volume":"63","author":"HJ Anders","year":"2003","unstructured":"Anders HJ, Vielhauer V, Schl\u00f6ndorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 2003;63:401\u201315.","journal-title":"Kidney Int"},{"key":"2597_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1755-1536-4-21","volume":"4","author":"WS To","year":"2011","unstructured":"To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenes Tissue Repair. 2011;4:21.","journal-title":"Fibrogenes Tissue Repair"},{"key":"2597_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellsig.2017.11.005","volume":"43","author":"SP Higgins","year":"2018","unstructured":"Higgins SP, Tang Y, Higgins CE, Mian B, Zhang W, Czekay RP, et al. TGF-\u03b21\/p53 signaling in renal fibrogenesis. Cell Signal. 2018;43:1\u201310.","journal-title":"Cell Signal"},{"key":"2597_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/ndt\/gfr567","volume":"27","author":"V Cernaro","year":"2012","unstructured":"Cernaro V, Lacquaniti A, Donato V, Fazio MR, Buemi A, Buemi M. Fibrosis, regeneration and cancer: what is the link? Nephrol Dial Transpl. 2012;27:21\u20137.","journal-title":"Nephrol Dial Transpl"},{"key":"2597_CR44","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.","journal-title":"Signal Transduct Target Ther"},{"key":"2597_CR45","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.21873\/invivo.12880","volume":"36","author":"M Satake","year":"2022","unstructured":"Satake M, Sakuraba H, Hiraga H, Yoshida S, Akemoto Y, Ota S, et al. Tacrolimus Up-regulates Expression of TGF\u03b2 Receptor Type II via ERK, Providing Protection Against Intestinal Epithelial Injury. Vivo. 2022;36:1684\u201393.","journal-title":"Vivo"},{"key":"2597_CR46","doi-asserted-by":"crossref","unstructured":"Jahr H, van der Windt AE, Timur UT, Baart EB, Lian WS, Rolauffs B, et al. Physosmotic Induction of Chondrogenic Maturation Is TGF-\u03b2 Dependent and Enhanced by Calcineurin Inhibitor FK506. Int J Mol Sci. 2022;23:5110.","DOI":"10.3390\/ijms23095110"},{"key":"2597_CR47","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.canlet.2021.08.002","volume":"520","author":"B Chandra Jena","year":"2021","unstructured":"Chandra Jena B, Sarkar S, Rout L, Mandal M. The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-\u03b2 in CAF mediated tumor progression and therapeutic resistance. Cancer Lett. 2021;520:222\u201332.","journal-title":"Cancer Lett"},{"key":"2597_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21:104.","journal-title":"Mol Cancer"},{"key":"2597_CR49","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.1158\/0008-5472.CAN-09-1404","volume":"69","author":"D Datta","year":"2009","unstructured":"Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, et al. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 2009;69:8902\u20139.","journal-title":"Cancer Res"},{"key":"2597_CR50","doi-asserted-by":"publisher","first-page":"e23919","DOI":"10.1371\/journal.pone.0023919","volume":"6","author":"A Basu","year":"2011","unstructured":"Basu A, Banerjee P, Contreras AG, Flynn E, Pal S. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One. 2011;6:e23919.","journal-title":"PLoS One"},{"key":"2597_CR51","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1111\/ajt.15483","volume":"19","author":"AE Rodriguez-Rodriguez","year":"2019","unstructured":"Rodriguez-Rodriguez AE, Donate-Correa J, Rovira J, Cuesto G, Luis-Ravelo D, Fernandes MX, et al. Inhibition of the mTOR pathway: A new mechanism of \u03b2 cell toxicity induced by tacrolimus. Am J Transpl. 2019;19:3240\u20139.","journal-title":"Am J Transpl"},{"key":"2597_CR52","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1016\/j.jacc.2019.03.499","volume":"73","author":"R Asleh","year":"2019","unstructured":"Asleh R, Clavell AL, Pereira NL, Smith B, Briasoulis A, Alnsasra H, et al. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. J Am Coll Cardiol. 2019;73:2676\u201388.","journal-title":"J Am Coll Cardiol"},{"key":"2597_CR53","first-page":"100040","volume":"5","author":"IL-S Reynold","year":"2020","unstructured":"Reynold IL-S, Panpan C, Lakshmi N, Ashar A, Sunil P, David JC. Sirolimus use improves cancer-free survival following transplantation: A single center 12-year analysis. Transplant Rep. 2020;5:100040.","journal-title":"Transplant Rep"},{"key":"2597_CR54","doi-asserted-by":"publisher","first-page":"e025507","DOI":"10.1161\/JAHA.122.025507","volume":"11","author":"PN Kampaktsis","year":"2022","unstructured":"Kampaktsis PN, Doulamis IP, Asleh R, Makri E, Kalamaras I, Papastergiopoulos C, et al. Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database. J Am Heart Assoc. 2022;11:e025507.","journal-title":"J Am Heart Assoc"},{"key":"2597_CR55","first-page":"2068","volume":"7","author":"SY Wen","year":"2014","unstructured":"Wen SY, Li CH, Zhang YL, Bian YH, Ma L, Ge QL, et al. Rictor is an independent prognostic factor for endometrial carcinoma. Int J Clin Exp Pathol. 2014;7:2068\u201378.","journal-title":"Int J Clin Exp Pathol"},{"key":"2597_CR56","doi-asserted-by":"publisher","first-page":"641453","DOI":"10.3389\/fonc.2021.641453","volume":"11","author":"RZ Cao","year":"2021","unstructured":"Cao RZ, Min L, Liu S, Tian RY, Jiang HY, Liu J, et al. Rictor Activates Cav 1 Through the Akt Signaling Pathway to Inhibit the Apoptosis of Gastric Cancer Cells. Front Oncol. 2021;11:641453.","journal-title":"Front Oncol"},{"key":"2597_CR57","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jclinpath-2016-203913","volume":"70","author":"T Sticz","year":"2017","unstructured":"Sticz T, Moln\u00e1r A, M\u00e1rk \u00c1, Hajdu M, Nagy N, V\u00e9gs\u0151 G, et al. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression. J Clin Pathol. 2017;70:410\u20136.","journal-title":"J Clin Pathol"},{"key":"2597_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.humpath.2019.08.018","volume":"93","author":"I Krencz","year":"2019","unstructured":"Krencz I, Sebestyen A, Papay J, Lou Y, Lutz GF, Majewicz TL, et al. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma. Hum Pathol. 2019;93:74\u201380.","journal-title":"Hum Pathol"},{"key":"2597_CR59","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/cncr.31782","volume":"125","author":"ME D\u2019Arcy","year":"2019","unstructured":"D\u2019Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019;125:933\u201342.","journal-title":"Cancer"},{"key":"2597_CR60","doi-asserted-by":"publisher","first-page":"120150","DOI":"10.1016\/j.lfs.2021.120150","volume":"288","author":"T Shigematsu","year":"2022","unstructured":"Shigematsu T, Tajima S, Fu R, Zhang M, Itoyama Y, Tsuchimoto A, et al. The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats. Life Sci. 2022;288:120150.","journal-title":"Life Sci"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02597-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02597-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02597-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T06:02:54Z","timestamp":1712124174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02597-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4,20]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02597-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"10 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The in vivo study presented in this paper was performed in accordance with the Declaration of Helsinki (1975) and conducted with valid official permissions (PEI\/001\/1733-2\/2015; approval: 14\/10\/2015). The study also received approval from the Institutional Animal Care Facility and the Institutional Ethical Review Board (PE\/EA\/801-7\/2020; approval: 16\/09\/2020). The use of human tissue samples was carried out with the approval of the Hungarian Scientific Council National Ethics Committee for Scientific Research (SE KREB-216\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}